Does the media favor OXB or AVCT?

In the previous week, Oxford Biomedica had 1 more articles in the media than Avacta Group. MarketBeat recorded 4 mentions for Oxford Biomedica and 3 mentions for Avacta Group. Oxford Biomedica's average media sentiment score of 0.47 beat Avacta Group's score of -0.24 indicating that Oxford Biomedica is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oxford Biomedica 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avacta Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SLN or AVCT?

Avacta Group has a consensus target price of GBX 99, indicating a potential upside of 37.50%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts plainly believe Avacta Group is more favorable than Silence Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts recommend HZD or AVCT?

Avacta Group has a consensus price target of GBX 99, suggesting a potential upside of 37.50%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts clearly believe Avacta Group is more favorable than Horizon Discovery Group plc (HZD.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Horizon Discovery Group plc (HZD.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media refer more to PRTC or AVCT?

In the previous week, Avacta Group had 2 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Avacta Group and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.00 beat Avacta Group's score of -0.24 indicating that PureTech Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avacta Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ARIX or AVCT?

Avacta Group has a consensus price target of GBX 99, suggesting a potential upside of 37.50%. Given Avacta Group's stronger consensus rating and higher possible upside, analysts clearly believe Avacta Group is more favorable than Arix Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arix Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Avacta Group (AVCT) Competitors

GBX 72 0.00 (0.00%)

As of 09/30/2026

Compare

AVCT vs. OXB, SLN, HZD, PRTC, and ARIX

Should you buy Avacta Group stock or one of its competitors? Avacta Group's main competitors and comparable companies include Oxford Biomedica (OXB), Silence Therapeutics (SLN), Horizon Discovery Group plc (HZD.L) (HZD), PureTech Health (PRTC), and Arix Bioscience (ARIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Avacta Group compare to Oxford Biomedica?

Oxford Biomedica (LON:OXB) and Avacta Group (LON:AVCT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

In the previous week, Oxford Biomedica had 1 more articles in the media than Avacta Group. MarketBeat recorded 4 mentions for Oxford Biomedica and 3 mentions for Avacta Group. Oxford Biomedica's average media sentiment score of 0.47 beat Avacta Group's score of -0.24 indicating that Oxford Biomedica is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Biomedica	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avacta Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oxford Biomedica has a net margin of -23.23% compared to Avacta Group's net margin of -35,730.97%. Oxford Biomedica's return on equity of -54.51% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-23.23%	-54.51%	-12.67%
Avacta Group	-35,730.97%	-1,293.07%	-21.80%

Avacta Group has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£175.36M	3.80	-£143.51M	-£26.92	N/A
Avacta Group	£113K	2,985.44	-£30.08M	-£9.66	N/A

Oxford Biomedica has a beta of 1.092, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Oxford Biomedica presently has a consensus price target of GBX 580.85, suggesting a potential upside of 5.42%. Avacta Group has a consensus price target of GBX 99, suggesting a potential upside of 37.50%. Given Avacta Group's stronger consensus rating and higher possible upside, analysts plainly believe Avacta Group is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

32.4% of Oxford Biomedica shares are held by institutional investors. Comparatively, 3.1% of Avacta Group shares are held by institutional investors. 43.3% of Oxford Biomedica shares are held by insiders. Comparatively, 47.7% of Avacta Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Oxford Biomedica and Avacta Group tied by winning 8 of the 16 factors compared between the two stocks.

How does Avacta Group compare to Silence Therapeutics?

Silence Therapeutics (LON:SLN) and Avacta Group (LON:AVCT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Silence Therapeutics has a net margin of 0.00% compared to Avacta Group's net margin of -35,730.97%. Silence Therapeutics' return on equity of 0.00% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	N/A	N/A	N/A
Avacta Group	-35,730.97%	-1,293.07%	-21.80%

3.1% of Avacta Group shares are held by institutional investors. 47.7% of Avacta Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Avacta Group has a consensus target price of GBX 99, indicating a potential upside of 37.50%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts plainly believe Avacta Group is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Silence Therapeutics has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A
Avacta Group	£113K	2,985.44	-£30.08M	-£9.66	N/A

In the previous week, Avacta Group had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 3 mentions for Avacta Group and 0 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.00 beat Avacta Group's score of -0.24 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Silence Therapeutics	Neutral
Avacta Group	Neutral

Summary

Avacta Group beats Silence Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Avacta Group compare to Horizon Discovery Group plc (HZD.L)?

Horizon Discovery Group plc (HZD.L) (LON:HZD) and Avacta Group (LON:AVCT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

Avacta Group has a consensus price target of GBX 99, suggesting a potential upside of 37.50%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts clearly believe Avacta Group is more favorable than Horizon Discovery Group plc (HZD.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Horizon Discovery Group plc (HZD.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

3.1% of Avacta Group shares are held by institutional investors. 47.7% of Avacta Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Avacta Group had 3 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 3 mentions for Avacta Group and 0 mentions for Horizon Discovery Group plc (HZD.L). Horizon Discovery Group plc (HZD.L)'s average media sentiment score of 0.00 beat Avacta Group's score of -0.24 indicating that Horizon Discovery Group plc (HZD.L) is being referred to more favorably in the media.

Company	Overall Sentiment
Horizon Discovery Group plc (HZD.L)	Neutral
Avacta Group	Neutral

Horizon Discovery Group plc (HZD.L) has a net margin of 0.00% compared to Avacta Group's net margin of -35,730.97%. Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A
Avacta Group	-35,730.97%	-1,293.07%	-21.80%

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A
Avacta Group	£113K	2,985.44	-£30.08M	-£9.66	N/A

Summary

Avacta Group beats Horizon Discovery Group plc (HZD.L) on 7 of the 13 factors compared between the two stocks.

How does Avacta Group compare to PureTech Health?

PureTech Health (LON:PRTC) and Avacta Group (LON:AVCT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

PureTech Health currently has a consensus target price of GBX 508, indicating a potential upside of 367.55%. Avacta Group has a consensus target price of GBX 99, indicating a potential upside of 37.50%. Given PureTech Health's higher probable upside, research analysts clearly believe PureTech Health is more favorable than Avacta Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Avacta Group had 2 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Avacta Group and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.00 beat Avacta Group's score of -0.24 indicating that PureTech Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avacta Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PureTech Health has a net margin of 7.53% compared to Avacta Group's net margin of -35,730.97%. PureTech Health's return on equity of 0.14% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	7.53%	0.14%	-13.39%
Avacta Group	-35,730.97%	-1,293.07%	-21.80%

PureTech Health has a beta of 0.771, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Avacta Group has lower revenue, but higher earnings than PureTech Health. Avacta Group is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£6.37M	41.85	-£91.86M	-£46.00	N/A
Avacta Group	£113K	2,985.44	-£30.08M	-£9.66	N/A

30.7% of PureTech Health shares are owned by institutional investors. Comparatively, 3.1% of Avacta Group shares are owned by institutional investors. 13.4% of PureTech Health shares are owned by insiders. Comparatively, 47.7% of Avacta Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

PureTech Health beats Avacta Group on 8 of the 14 factors compared between the two stocks.

How does Avacta Group compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and Avacta Group (LON:AVCT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

41.3% of Arix Bioscience shares are owned by institutional investors. Comparatively, 3.1% of Avacta Group shares are owned by institutional investors. 20.7% of Arix Bioscience shares are owned by company insiders. Comparatively, 47.7% of Avacta Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Arix Bioscience has a net margin of 105.64% compared to Avacta Group's net margin of -35,730.97%. Arix Bioscience's return on equity of 6.41% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arix Bioscience	105.64%	6.41%	2.18%
Avacta Group	-35,730.97%	-1,293.07%	-21.80%

Avacta Group has a consensus price target of GBX 99, suggesting a potential upside of 37.50%. Given Avacta Group's stronger consensus rating and higher possible upside, analysts clearly believe Avacta Group is more favorable than Arix Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arix Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Arix Bioscience has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Arix Bioscience has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A
Avacta Group	£113K	2,985.44	-£30.08M	-£9.66	N/A

In the previous week, Avacta Group had 3 more articles in the media than Arix Bioscience. MarketBeat recorded 3 mentions for Avacta Group and 0 mentions for Arix Bioscience. Arix Bioscience's average media sentiment score of 0.00 beat Avacta Group's score of -0.24 indicating that Arix Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Arix Bioscience	Neutral
Avacta Group	Neutral

Summary

Arix Bioscience beats Avacta Group on 9 of the 15 factors compared between the two stocks.

Get Avacta Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVCT vs. The Competition

Export

Metric	Avacta Group	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£337.36M	£3.84B	£7.13B	£2.81B
Dividend Yield	3.97%	3.64%	2.53%	6.18%
P/E Ratio	-7.45	13.60	273.99	366.21
Price / Sales	2,985.44	1,296.00	608.65	89,367.96
Price / Cash	15.00	121.76	77.38	27.89
Price / Book	4.89	16.57	10.88	6.79
Net Income	-£30.08M	-£22.67M	£3.50B	£5.89B
7 Day Performance	-1.10%	-2.20%	-1.62%	-0.59%
1 Month Performance	7.46%	-10.00%	-5.90%	17.02%
1 Year Performance	15.20%	22.34%	9.47%	16.67%

Avacta Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVCT Avacta Group	2.102 of 5 stars	GBX 72 flat	GBX 99 +37.5%	+17.1%	£337.36M	£113K	N/A	120	Earnings Report
OXB Oxford Biomedica	2.301 of 5 stars	GBX 507 +3.5%	GBX 580.85 +14.6%	-13.6%	£613.71M	£175.36M	N/A	891	Gap Up
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
PRTC PureTech Health	2.7858 of 5 stars	GBX 114.40 -1.4%	GBX 508 +344.1%	-20.1%	£280.49M	£6.37M	N/A	300	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:AVCT) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avacta Group (AVCT) Competitors

AVCT vs. OXB, SLN, HZD, PRTC, and ARIX

How does Avacta Group compare to Oxford Biomedica?

Summary

How does Avacta Group compare to Silence Therapeutics?

Summary

How does Avacta Group compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Avacta Group compare to PureTech Health?

Summary

How does Avacta Group compare to Arix Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVCT vs. The Competition

Avacta Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avacta Group (AVCT) Competitors

AVCT vs. OXB, SLN, HZD, PRTC, and ARIX

How does Avacta Group compare to Oxford Biomedica?

Does the media favor OXB or AVCT?

Is OXB or AVCT more profitable?

Which has stronger valuation & earnings, OXB or AVCT?

Which has more risk and volatility, OXB or AVCT?

Do analysts recommend OXB or AVCT?

Do institutionals and insiders have more ownership in OXB or AVCT?

Summary

How does Avacta Group compare to Silence Therapeutics?

Is SLN or AVCT more profitable?

Do insiders and institutionals believe in SLN or AVCT?

Do analysts rate SLN or AVCT?

Which has preferable earnings & valuation, SLN or AVCT?

Does the media favor SLN or AVCT?

Summary

How does Avacta Group compare to Horizon Discovery Group plc (HZD.L)?

Do analysts recommend HZD or AVCT?

Do institutionals and insiders have more ownership in HZD or AVCT?

Does the media prefer HZD or AVCT?

Is HZD or AVCT more profitable?

Which has higher earnings and valuation, HZD or AVCT?

Summary

How does Avacta Group compare to PureTech Health?

Do analysts rate PRTC or AVCT?

Does the media refer more to PRTC or AVCT?

Is PRTC or AVCT more profitable?

Which has more volatility and risk, PRTC or AVCT?

Which has stronger valuation & earnings, PRTC or AVCT?

Do institutionals and insiders hold more shares of PRTC or AVCT?

Summary

How does Avacta Group compare to Arix Bioscience?

Do institutionals and insiders have more ownership in ARIX or AVCT?

Is ARIX or AVCT more profitable?

Do analysts prefer ARIX or AVCT?

Which has more volatility & risk, ARIX or AVCT?

Which has higher valuation and earnings, ARIX or AVCT?

Does the media refer more to ARIX or AVCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVCT vs. The Competition

Avacta Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools